Haematology

Doç. Dr. Senem Maral

Doctor and researcher Medipol Mega Üniversite Hastanesi İstanbul
Multiple MyelomaLymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphoma, Large B-Cell, DiffuseInfectionsGraft vs Host DiseaseLeukemia, Hairy CellHypercalcemiaLeukemia, Plasma CellLeukemia, Myeloid, AcuteThrombosisHemophilia A
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Multiple Myeloma 6 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lymphoma 4 publications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 publications
  • Lymphoma, Large B-Cell, Diffuse 3 publications
  • Infections 2 publications
  • Graft vs Host Disease 2 publications
  • Leukemia, Hairy Cell 2 publications
  • Hypercalcemia 2 publications
  • Leukemia, Plasma Cell 2 publications
  • Leukemia, Myeloid, Acute 2 publications
  • Thrombosis 2 publications
  • Hemophilia A 2 publications

Person ↔ Disease

Which topics does this doctor work on?

From source

Medical areas of interest stated by the doctor on the institution profile. Source: medipol.com.tr.

  • Klinik Çalışmalar
  • Multipl Myelom
  • Deri Lenfomaları

CV

Education and experience

From source

Experience

  • ExperienceANKARA ÇAMLICA SAĞLIK OCAĞImedipol.com.tr
  • ExperienceANKARA ABDURRAHMAN YURTARSLAN ONKOLOJİ EĞİTİM VE ARAŞTIRMA HASTANESİmedipol.com.tr
  • ExperienceANKARA SİNCAN F TİPİ CEZA İNFAZ KURUMLARI KAMPUS DEVLET HASTANESİmedipol.com.tr
  • ExperienceANKARA DIŞKAPI YILDIRIM BEYAZIT EĞİTİM ARAŞTIRMA HASTANESİmedipol.com.tr

Education

  • 2017ANKARA EĞİTİM ARAŞTIRMA HASTANESİ, HEMATOLOJİmedipol.com.tr
  • 2012FATİH ÜNİVERSİTESİ, İÇ HASTALIKLARImedipol.com.tr
  • 2006KOCAELİ ÜNİVERSİTESİ, TIP FAKÜLTESİmedipol.com.tr

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologymedipol.com.trFrom source
  • InstitutionMedipol Mega Üniversite Hastanesimedipol.com.trFrom source
  • Area of workMultiple MyelomaExtracted from 6 publications · Model version —From source
  • Publications152 publicationsOpenAlexFrom source
  • Languagesİngilizcemedipol.com.trFrom source
  • Last synchronised4 November 2026 20:29https://medipol.com.tr/doktorlarimiz/docdr-senem-maralmedipol.com.tr

Scientific work

Publications on Multiple Myeloma

152 publications

  1. Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020453 PMID 41598391 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Real-World Experience with Belinostat in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

    Annals of Medical Research, 2026

    DOI 10.5455/annalsmedres.2025.07.193 Open-access full textSource: OpenAlex

  3. A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15145401 PMID 42513315 Open-access full textSource: OpenAlex

  4. Enterovirus Encephalitis Developing After Treatment for Follicular Lymphoma: A Case Report

    SN Comprehensive Clinical Medicine, 2026

    DOI 10.1007/s42399-026-02560-z Source: OpenAlex

  5. Real-World Effectiveness and Renal Safety of Foscarnet for CMV Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166365 PMID 42652768 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  6. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2603870 PMID 42212933 7 citations (Europe PMC) Source: OpenAlex

  7. Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

    New England Journal of Medicine, 2026

    DOI 10.1056/nejmoa2604657 PMID 42294841 8 citations (Europe PMC) Source: OpenAlex

  8. MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.7507 Source: OpenAlex

  9. POSTER: MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)01331-5 Source: OpenAlex

  10. MM-593: Phase 3 Randomized Study of Talquetamab + Daratumumab ± Pomalidomide vs Daratumumab + Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3

    Clinical Lymphoma Myeloma & Leukemia, 2026

    DOI 10.1016/s2152-2650(26)02897-1 Source: OpenAlex

View all 152 publications